Anti-amyloid antibodies are the first disease-modifying treatments for Alzheimer's disease. Aducanumab (Aduhelm — controversial accelerated approval, later effectively withdrawn from market), lecanemab (Leqembi, full approval 2023), and donanemab (Kisunla, approval 2024) target amyloid-beta plaques and clear them from the brain. The clinical claim is that reducing amyloid burden slows cognitive decline — and the trial data, modestly, support that claim.
- Class
- Monoclonal anti-amyloid antibodies
- Mechanism
- Bind and clear amyloid-beta plaques from brain → reduce amyloid burden → slow cognitive decline (modest effect in early Alzheimer's)
- Typical dose
- IV infusions every 2-4 weeks (drug-specific)
- Half-life
- Long — weeks
- FDA indications
- Early Alzheimer's disease (MCI due to AD or mild Alzheimer's dementia) with confirmed amyloid pathology
- Key adverse effects
- ARIA (amyloid-related imaging abnormalities) — ARIA-E (edema), ARIA-H (microhemorrhages, larger hemorrhages); infusion reactions; headache
- Representative agents
- Lecanemab (Leqembi), donanemab (Kisunla). Aducanumab/Aduhelm is historical/discontinued.
Black box: ARIA risk — periodic MRI monitoring required. Increased ARIA risk in ApoE4 homozygotes.
First disease-modifying Alzheimer's drugs. Effect size modest (slow decline by ~25-35%). ARIA is the main safety concern — frequent MRIs, monitoring protocols. Cost very high. APOE4 genotyping affects risk stratification. Restricted to early disease — not for moderate-severe.
Indication: early Alzheimer's disease — mild cognitive impairment due to AD or mild dementia stage — with confirmed amyloid pathology by PET imaging or CSF biomarkers. This is not a treatment for advanced disease; the antibodies are not approved for moderate or severe dementia. The amyloid biomarker confirmation matters: clinically diagnosed "Alzheimer's" without biomarker confirmation has substantial misclassification, and treating non-amyloid pathology with anti-amyloid antibodies wouldn't help.
Anti-amyloid antibodies are the first genuinely disease-modifying Alzheimer's treatments — monoclonal antibodies that clear amyloid plaque rather than supporting neurotransmission.
Mechanism note: Anti-amyloid antibodies are the first disease-modifying Alzheimer's drugs — they clear plaque and modestly slow decline, but the ARIA risk, monitoring burden, and cost make candidate selection a careful, biomarker-driven decision.
The effect size is modest: cognitive decline slowed approximately 25-35 percent over 18 months in trials. The patient and family will not experience dramatic cognitive recovery. They may experience slower progression — which over years could mean meaningful preservation of function, but not reversal.
ARIA — amyloid-related imaging abnormalities — is the central safety concern. Vasogenic edema (ARIA-E) and microhemorrhages (ARIA-H) emerge in a substantial portion of treated patients, particularly APOE4 homozygotes who carry roughly threefold higher ARIA risk. Most ARIA is asymptomatic and self-limited; some is severe and rarely fatal. Periodic MRI monitoring is required (baseline, then at specified intervals during the infusion schedule).
Logistics: IV infusions every 2-4 weeks depending on agent. Substantial cost — these are among the most expensive psychiatric/neurologic treatments. Frequent MRI monitoring. APOE genotyping for risk stratification before treatment. Specialized infusion infrastructure. The infrastructure burden is substantial; access varies by geography and insurance.
- Cost
- Lecanemab (Leqembi) ~$26,000/year. Donanemab (Kisunla) similar. Plus MRI monitoring, infusion infrastructure.
- Generic status
- No generic; novel biologics.
- Formulary typical
- Medicare Part B coverage with criteria (CMS expanded coverage 2023+). Commercial coverage variable. Patient OOB substantial even when covered.
- Access friction
- Infrastructure substantial: amyloid biomarker confirmation (PET or CSF), MRI monitoring schedule, IV infusion center, APOE genotyping for risk stratification. Many systems have specific clinics for these treatments.
Prescriber tip: Not a routine outpatient psychiatric prescription. Refer to specialized memory disorders or neurology programs that have the infrastructure for amyloid PET, infusion, MRI monitoring.
Shared decision-making is essential. The patient and family deserve honest framing: modest benefit, real risks, substantial burden, restriction to early-disease patients with confirmed amyloid. For the right patient with the right disease stage and the right access, anti-amyloid antibodies represent the first genuine disease modification in Alzheimer's. The field is still learning what role they will ultimately play.